Brockmann Bobbi Jo 4

What Happened
Bobbi Jo Brockmann, Vice President of Sales and Marketing and a director of Immucell Corp. (ICCC), was granted options to acquire 100,000 shares on January 27, 2026. The grant is recorded as a derivative award at an acquisition price of $0.00 (no cash paid at grant). This is a compensation award (not a purchase or sale) and does not represent an immediate sale or exercise.

Key Details

• Transaction date: 2026-01-27 (reported on Form 4 filed 2026-01-29). Filing appears to be within the standard two-business-day Form 4 window.
• Transaction type/code: Grant/Award (derivative instrument, code A).
• Amount: Options to acquire 100,000 shares; acquisition price reported as $0.00 (value at grant not provided in filing).
• Vesting/footnote: The option will be treated as an incentive stock option (ISO) to the extent allowed by law, with the remainder as a nonqualified stock option. Vesting: 33,333 shares exercisable on Jan 27, 2027; 33,333 on Jan 27, 2028; and 33,334 on Jan 27, 2029.
• Shares owned after transaction: Not disclosed in the provided filing.
• No immediate exercise or sale reported — this is a grant subject to future vesting/possible exercise.

Context
This is a standard equity compensation grant to an executive/director. Derivative awards like stock options give the holder the right to buy shares later (subject to vesting and exercise rules) and do not reflect an immediate cash transaction or liquidation. For retail investors, such grants indicate company compensation practices but should not be interpreted alone as a direct buy/sell signal.